- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04572256
MOntelukast as a Potential CHondroprotective Treatment Following Anterior Cruciate Ligament Reconstruction (MOCHA Trial) (MOCHA)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
After anterior cruciate ligament (ACL) reconstruction, patient-reported outcomes are improved 10 years post-surgery. Cytokine concentrations, however, remain elevated years after surgery; over 80% of patients with combined ACL and meniscus injuries have post-traumatic osteoarthritis (PTOA) within 10-15 years after injury. Since pain nociceptors are not located in the articular cartilage, patient-reported outcomes improve despite progressive, irreversible cartilage loss, thus making PTOA a "silent killer." Because early cartilage loss progresses without pain and dysfunction, the prevalence of PTOA continues to increase. PTOA now represents the most common cause of military disability.
Our recent results illustrate the downstream cytokine and degradative enzyme activity following ACL reconstruction. ACL and meniscus injury initiate a biochemical cascade resulting in cartilage degradation and this process involves an up-regulated pro-inflammatory response with a dysregulated anti-inflammatory response. Single-dose intra-articular anti-inflammatory treatment appears to reduce hyaline cartilage degradation shortly after the time of injury based on synovial fluid measures of type II collagen degradation. The intra-articular inflammatory milieu at the time of surgery appears to predict the patient symptom state two years later; however, the effectiveness of preoperative anti-inflammatory treatments in impacting patient symptoms or slowing long-term PTOA progression is as yet unclear. A lack of efficacy in preoperative interventions may be attributed to a profound inflammatory stimulus from surgical reconstruction of the ACL. The postoperative inflammatory cascade results in articular cartilage and meniscus degradation due to matrix degrading enzymes, especially those which breakdown type II collagen.
PTOA affects the whole joint organ including the cartilage, synovium, and bone. PTOA progression is multifaceted and includes activation of the pro-inflammatory Nuclear Factor Kappa-B (NFkB) pathway, an increase in pro-inflammatory M1 macrophages, cell senescence, and bone remodeling. Limiting the biochemical cascade through an innovative disease modifying treatment to target upstream activity will potentially treat all components of the knee, thereby lessening the inflammatory response, reducing cartilage catabolism, and potentially improving pathologic bony remodeling observed after ACL reconstruction. The early proteomic PTOA response is more similar to inflammatory rheumatoid arthritis than idiopathic OA; thus, long-acting agents which better regulate pro-inflammatory cytokine activity may more successfully limit tissue destruction. By re-purposing approved therapeutics with proven immune efficacy, a readily-available and cost-effective strategy for disease modification may be possible.
Montelukast was first approved for clinical use in 1998 for prophylaxis and chronic treatment of asthma. The drug selectively inhibits the cysteinyl leukotriene receptor 1 (CysLT1). Montelukast blocks the actions of cysteinyl leukotriene D4 (LTD4), which is produced through the arachidonic acid pathway. This pro-inflammatory signal is released from several cells including the inflammatory mast cells and eosinophils. Montelukast also appears to address multiple PTOA mechanisms by inhibiting cysteinyl leukotrienes. Cysteinyl leukotriene inhibition in animal and laboratory models of PTOA resulted in the elimination of senescent cells, reduced NFkB activation, decreased concentrations of pro-inflammatory and catabolic factors and reactive oxygen species (ROS) while increasing expression of anti-inflammatory factors (inducing anti-inflammatory M2 macrophage infiltration), inhibiting osteoclastogenesis and improving bone quality. The novel use of oral montelukast offers the potential of a disease modifying treatment to prevent irreversible cartilage loss after ACL injury.
Study Type
Enrollment (Estimated)
Phase
- Early Phase 1
Contacts and Locations
Study Contact
- Name: Austin Stone, MD, PhD
- Phone Number: 859.218.3065
- Email: austin.stone@uky.edu
Study Locations
-
-
Kentucky
-
Lexington, Kentucky, United States, 40504
- Recruiting
- UK Healthcare at Turfland
-
Contact:
- Austin Stone, MD, PhD
- Phone Number: 859-218-3065
- Email: austin.stone@uky.edu
-
Sub-Investigator:
- Cale Jacobs, PhD
-
Principal Investigator:
- Austin Stone, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Undergoing primary ACL reconstruction
- Age between 25-50
- Concomitant meniscus injury
Exclusion Criteria:
- Undergoing revision procedures
- Multiple ligament injuries requiring multiple ligament reconstruction/repair
- Depressive symptoms and/or those who endorse suicidal ideation at the time of enrollment (PHQ-9 score >= 15)
- Found to not have a meniscus tear at the time of surgery
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Montelukast
Patients will receive oral montelukast (10 mg) daily for 6 months after surgery.
|
The novel use of oral montelukast offers the potential of a disease modifying treatment to prevent irreversible cartilage loss after ACL injury.
10mg of oral Montelukast will be taken daily for 6 months post surgery.
Other Names:
|
Placebo Comparator: Placebo
Patients will receive an oral placebo daily for 6 months after surgery.
|
An oral placebo will be taken daily for 6 months post surgery.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Serum prostaglandin E2
Time Frame: Change between Visit 3 (10 days post surgery) and Visit 6 (1 year post surgery)
|
Prostaglandin E2 is a potential inflammatory mediator, and it is being measured to directly assess whether treatment reduces this systemic inflammatory marker.
Greater serum prostaglandin is associated with greater inflammation.
|
Change between Visit 3 (10 days post surgery) and Visit 6 (1 year post surgery)
|
T1rho relaxation time on MRI
Time Frame: Change between Visit 4 (4 weeks post surgery) and Visit 6 (1 year post surgery)
|
T1rho relaxation time is a validated measure of proteoglycan content within the cartilage, and can be assessed on MRI.
Increased T1rho relaxation time is associated with increased cartilage degeneration.
|
Change between Visit 4 (4 weeks post surgery) and Visit 6 (1 year post surgery)
|
Shape of the medial femoral condyle on MRI
Time Frame: Change between Visit 4 (4 weeks post surgery) and Visit 6 (1 year post surgery)
|
The shape of the medial femoral condyle has been previously demonstrated to change after ACL reconstruction and is predictive of later cartilage changes.
Flattening and widening of the medial femoral condyle are considered to be indicative of later cartilage changes.
|
Change between Visit 4 (4 weeks post surgery) and Visit 6 (1 year post surgery)
|
Knee injury and Osteoarthritis Outcome Score (KOOS)
Time Frame: Change between Visit 3 (10 days post surgery) and Visit 6 (1 year post surgery)
|
The KOOS is a patient-reported outcome instrument that is comprised of 5 subscales (Pain, Symptoms, Activities of Daily Living, Sports and Recreation, and Quality of Life) with each scale being scored from 0 to 100 with higher scores being indicative of a superior outcome.
|
Change between Visit 3 (10 days post surgery) and Visit 6 (1 year post surgery)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Austin Stone, MD, PhD, University of Kentucky
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Wounds and Injuries
- Leg Injuries
- Joint Diseases
- Musculoskeletal Diseases
- Rheumatic Diseases
- Arthritis
- Knee Injuries
- Osteoarthritis
- Anterior Cruciate Ligament Injuries
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Anti-Asthmatic Agents
- Respiratory System Agents
- Leukotriene Antagonists
- Hormone Antagonists
- Cytochrome P-450 CYP1A2 Inducers
- Cytochrome P-450 Enzyme Inducers
- Montelukast
Other Study ID Numbers
- 60266
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Post-traumatic Osteoarthritis
-
Zimmer, GmbHTerminatedKnee Osteoarthritis | Post-traumatic OsteoarthritisUnited Kingdom, Germany, Netherlands
-
J L MarshUnited States Department of DefenseCompletedOsteoarthritis | Post-traumatic OsteoarthritisUnited States
-
James StannardCompletedPost-traumatic OsteoarthritisUnited States
-
Istituto Ortopedico RizzoliCompletedPost-traumatic Osteoarthritis | Hip OsteoarthritisItaly
-
Affinity Health Research InstituteGenesis Orthopedics and Sports Medicine; The Center for Primary Care and Sports...UnknownPost-Traumatic Osteoarthritis of KneeUnited States
-
University Hospital, GhentCompletedOsteoarthritis Thumb | Post-traumatic; ArthrosisBelgium
-
Zimmer BiometActive, not recruitingRheumatoid Arthritis | Knee Osteoarthritis | Post-traumatic OsteoarthritisAustria
-
Sport Injury Prevention Research CentreUnknownOsteoarthritis Knees Both Post-TraumaticCanada
-
Brigham and Women's HospitalArthritis FoundationNot yet recruitingOsteoarthritis, Knee | Post-traumatic Osteoarthritis | ACL TearUnited States
-
United States Naval Medical Center, San DiegoNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and other collaboratorsNot yet recruitingTibial Fractures | Post-traumatic; Arthrosis | Post-Traumatic Osteoarthritis of Ankle
Clinical Trials on Montelukast
-
Indiana UniversityCompleted
-
Chinese University of Hong KongUniversity of Sydney; Chongqing Medical University; Hong Kong University of Science... and other collaboratorsNot yet recruitingAtherosclerosis, CoronaryHong Kong
-
GlaxoSmithKlineCompleted
-
Kecioren Education and Training HospitalCompletedAsthma | Acute AsthmaTurkey
-
Menarini International Operations Luxembourg SACompletedAsthma | Seasonal Allergic RhinoconjunctivitisPoland, Romania, Germany, Italy, Czechia, Latvia, Croatia, Slovakia
-
Organon and CoCompleted
-
Medical University of LodzUnknownSeasonal Allergic RhinitisPoland
-
GlaxoSmithKlineCompletedRespiratory Disorders | Asthma and RhinitisIndia
-
Qilu Pharmaceutical Co., Ltd.Completed
-
Kecioren Education and Training HospitalCompletedAcute Asthma | Acute Wheezy BronchitisTurkey